Journal issues > Issue 3, September 2015 > Optimizing patient outcomes in CML

Optimizing patient outcomes in CML

summary

Imatinib has drastically changed the outcome of patients with chronic myeloid leukemia (CML), offering the majority of patients a normal life span. More recently, the development of second, and third generation tyrosine kinase inhibitors and the advent of treatment discontinuation in CML made the management of these patients more challenging. Currently, three tyrosine kinase inhibitors are available in the first-line treatment of CML patients: imatinib, nolitinib and dasatinib. During several satellite symposia, hosted by Novartis during the 2015 annual meeting of the European Hematology Association (EHA), a panel of experts discussed the different aspects that need to be kept in mind when making treatment decisions in CML patients.

(BELG J HEMATOL 2015;6(3):85–7)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top